Precision Medicine and PET–Computed Tomography in Pediatric Malignancies

Yasemin Sanli; Ebru Yilmaz; Rathan M. Subramaniam

doi:10.1016/j.cpet.2017.05.009

Precision Medicine and PET–Computed Tomography in Pediatric Malignancies

Yasemin Sanli, Ebru Yilmaz, Rathan M. Subramaniam

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Fluorine-18 fluorodeoxyglucose (¹⁸F-FDG) PET–computed tomography (CT) plays a significant role in diagnosis, staging, therapy selection, and therapy assessment of multiple pediatric malignancies and facilitating precision medicine delivery in pediatric patients. In patients with Hodgkin lymphoma, interim fludeoxyglucose ¹⁸F-FDG PET/CT is highly sensitive and specific for predicting survival and multiple trials with FDG PET/CT–based adaptive therapies are currently ongoing. It is superior to iodine-131 metaiodobenzylguanidine (¹³¹I-MIBG) scintigraphy and bone scintigraphy for detecting metastases in neuroblastoma patients and sarcoma patients. It may predict histologic differentiation and neoadjuvant therapy assessment in Wilms tumor.

Original language	English (US)
Pages (from-to)	423-435
Number of pages	13
Journal	PET Clinics
Volume	12
Issue number	4
DOIs	https://doi.org/10.1016/j.cpet.2017.05.009
State	Published - Oct 2017

Keywords

PET
PET/CT
Pediatric malignancies

ASJC Scopus subject areas

Radiation
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.cpet.2017.05.009

Cite this

@article{ce65e44e8767422c9c06cbd074cc4ebc,

title = "Precision Medicine and PET–Computed Tomography in Pediatric Malignancies",

abstract = "Fluorine-18 fluorodeoxyglucose (18F-FDG) PET–computed tomography (CT) plays a significant role in diagnosis, staging, therapy selection, and therapy assessment of multiple pediatric malignancies and facilitating precision medicine delivery in pediatric patients. In patients with Hodgkin lymphoma, interim fludeoxyglucose 18F-FDG PET/CT is highly sensitive and specific for predicting survival and multiple trials with FDG PET/CT–based adaptive therapies are currently ongoing. It is superior to iodine-131 metaiodobenzylguanidine (131I-MIBG) scintigraphy and bone scintigraphy for detecting metastases in neuroblastoma patients and sarcoma patients. It may predict histologic differentiation and neoadjuvant therapy assessment in Wilms tumor.",

keywords = "PET, PET/CT, Pediatric malignancies",

author = "Yasemin Sanli and Ebru Yilmaz and Subramaniam, {Rathan M.}",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Inc.",

year = "2017",

month = oct,

doi = "10.1016/j.cpet.2017.05.009",

language = "English (US)",

volume = "12",

pages = "423--435",

journal = "PET Clinics",

issn = "1556-8598",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - Precision Medicine and PET–Computed Tomography in Pediatric Malignancies

AU - Sanli, Yasemin

AU - Yilmaz, Ebru

AU - Subramaniam, Rathan M.

PY - 2017/10

Y1 - 2017/10

N2 - Fluorine-18 fluorodeoxyglucose (18F-FDG) PET–computed tomography (CT) plays a significant role in diagnosis, staging, therapy selection, and therapy assessment of multiple pediatric malignancies and facilitating precision medicine delivery in pediatric patients. In patients with Hodgkin lymphoma, interim fludeoxyglucose 18F-FDG PET/CT is highly sensitive and specific for predicting survival and multiple trials with FDG PET/CT–based adaptive therapies are currently ongoing. It is superior to iodine-131 metaiodobenzylguanidine (131I-MIBG) scintigraphy and bone scintigraphy for detecting metastases in neuroblastoma patients and sarcoma patients. It may predict histologic differentiation and neoadjuvant therapy assessment in Wilms tumor.

AB - Fluorine-18 fluorodeoxyglucose (18F-FDG) PET–computed tomography (CT) plays a significant role in diagnosis, staging, therapy selection, and therapy assessment of multiple pediatric malignancies and facilitating precision medicine delivery in pediatric patients. In patients with Hodgkin lymphoma, interim fludeoxyglucose 18F-FDG PET/CT is highly sensitive and specific for predicting survival and multiple trials with FDG PET/CT–based adaptive therapies are currently ongoing. It is superior to iodine-131 metaiodobenzylguanidine (131I-MIBG) scintigraphy and bone scintigraphy for detecting metastases in neuroblastoma patients and sarcoma patients. It may predict histologic differentiation and neoadjuvant therapy assessment in Wilms tumor.

KW - PET

KW - PET/CT

KW - Pediatric malignancies

UR - http://www.scopus.com/inward/record.url?scp=85026325471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026325471&partnerID=8YFLogxK

U2 - 10.1016/j.cpet.2017.05.009

DO - 10.1016/j.cpet.2017.05.009

M3 - Review article

C2 - 28867113

AN - SCOPUS:85026325471

SN - 1556-8598

VL - 12

SP - 423

EP - 435

JO - PET Clinics

JF - PET Clinics

IS - 4

ER -

Precision Medicine and PET–Computed Tomography in Pediatric Malignancies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this